ADVANCED SOLUTIONS FOR SKIN CANCER TREATMENT
At Sensus Healthcare, we take pride in offering cutting-edge technology designed to revolutionize the treatment of keloids and skin cancer. Our innovative devices—the SRT-100, SRT-100+, and SRT-100 Vision (IG-SRT)—combine precision, efficacy, and patient comfort to deliver unparalleled results
At Sensus Healthcare, we are committed to advancing the field of skin cancer treatment through innovation and excellence. With our comprehensive suite of SRT devices, we provide physicians and their staff with the tools they need to deliver superior care and improve the lives of patients worldwide.
IG-SRT
Our latest innovation, the SRT-100 Vision also known as IG-SRT or Image-Guided Superficial Radiotherapy, combines state-of-the-art technology with unparalleled convenience. This revolutionary device features integrated imaging and treatment planning capabilities, allowing physicians to visualize the treatment area in real-time and tailor treatment plans with unmatched precision. With its intuitive interface and seamless integration, the SRT-100 Vision empowers physicians to deliver personalized care and superior outcomes for every patient.
As the market leader in non-invasive non-melanoma skin cancer (NMSC) treatment, Sensus Healthcare is proud to introduce another proven technology to cutaneous radiation oncology — High-Frequency Ultrasound for Image Guidance. With this exclusive feature of the SRT-100 VisionTM, you can now see and assess the lesions you treat and track treatment progress like never before.
Building on the success of the SRT-100, the SRT-100+ introduces enhanced features and capabilities to further elevate the treatment experience. With advanced dosimetry options, improved energy delivery, and expanded treatment capabilities, the SRT-100+ offers even greater precision and flexibility. Designed with both patients and physicians in mind, the SRT-100+ sets a new standard for excellence in superficial radiation therapy.
The SRT-100 represents the gold standard in superficial radiotherapy for non-melanoma skin cancer. The SRT-100 represents the gold standard in superficial radiotherapy for non-melanoma skin cancer and the treatment of keloids. All 3 of Sensus Healthcare’s SRT devices are FDA-cleared. The SRT-100 offers targeted treatment directly to the skin cancer lesion, sparing surrounding healthy tissue and minimizing side effects. With its user-friendly interface and customizable treatment parameters, the SRT-100 provides physicians with the tools they need to deliver optimal outcomes for their patients. This device is most commonly sold in worldwide International Markets.
To learn more about our international sales, click here
